X

Trial Profile

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avadomide (Primary) ; Onatasertib (Primary) ; Rituximab (Primary) ; Spebrutinib (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions
Sponsors Celgene Corporation

Most Recent Events

16 Jan 2024 Status changed from active, no longer recruiting to discontinued. (Replaced with another clinical trial.)
10 Nov 2023 Planned End Date changed from 31 Oct 2023 to 31 Jan 2024.
10 Nov 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com